AOD-9604
Tested in peopleGet notified when the evidence changes.
It has been tested in people, but it is not an approved medicine. The studies are usually small.
Compiled and reviewed by the PeptideSearch Editorial Team · Status checked 2024-09-27
Also called hGH Fragment 176-191 / AOD9604 / Tyr-hGH 177-191
A small piece of growth hormone tested for weight loss in people. It did not beat placebo in the main trials.
Official status: Not nominated for 503A compounding · Checked 2024-09-27
Can a doctor prescribe this?
- Small pharmacy (503A)
- Never put forward to FDA
- Large outsourcing facility (503B)
- Never put forward to FDA
Left the FDA's restricted category in September 2024 when its nomination was withdrawn. It is not on the approved compounding list.
503A is a pharmacy making a single prescription for one patient. 503B is a facility making batches. They are governed by separate lists. Where a category is shown, it is a position on the FDA's list of substances that have been put forward and are still being worked through — not the final list, which is set by rulemaking. Category 1 means the FDA does not plan to act against a pharmacy that makes it while the review runs.
Lab suppliers we list: 13
Doses used in research
Taken word for word from the studies and trials listed on this page. This is not a recommendation and not a dose for anyone to take.
- Animal study, larger animalsEffect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model.
Annals of clinical and laboratory science · 2015
- Animal study, larger animalsGateways to clinical trials.
Methods and findings in experimental and clinical pharmacology · 2005
- Animal study, rats or miceThe effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice.
Endocrinology · 2001
- Animal study, rats or miceMetabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone.
Hormone research · 2000
- Lab dish studyDetection and in vitro metabolism of AOD9604.
Drug testing and analysis · 2015
- Lab dish studyIncrease of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment.
International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity · 2001
- Lab test method, not a health studyRapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices.
The Analyst · 2026
- Lab test method, not a health studySimplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry.
Journal of separation science · 2016
- Lab test method, not a health studyAnalytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls.
Journal of pharmaceutical and biomedical analysis · 2014
- Lab test method, not a health studyIdentification and characterization of peptide drugs in unknown pharmaceutical preparations seized by the Belgian authorities: case report on AOD9604.
Drug testing and analysis · 2014
- Lab test method, not a health studyDetecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions.
Expert review of proteomics · 2014
- Lab test method, not a health studyAOD-9604 does not influence the WADA hGH isoform immunoassay.
Drug testing and analysis · 2013
- Hypothesis, not a tested studyPotential role of new therapies in modifying cardiovascular risk in overweight patients with metabolic risk factors.
Obesity (Silver Spring, Md.) · 2006
- Hypothesis, not a tested studyAOD-9604 Metabolic.
Current opinion in investigational drugs (London, England : 2000) · 2004
- Gateways to clinical trials.
Methods and findings in experimental and clinical pharmacology · 2003
- Gateways to clinical trials.
Methods and findings in experimental and clinical pharmacology · 2003
- Review of earlier workThe emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.
Frontiers in endocrinology · 2026
- Review of earlier workSafety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.
Sports medicine (Auckland, N.Z.) · 2026
- Review of earlier workTherapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.
Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2026
- Review of earlier workHuman Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells.
Drug design, development and therapy · 2022
- Review of earlier workCurrent updates in the medical management of obesity.
Recent patents on endocrine, metabolic & immune drug discovery · 2012
- Review of earlier work[Obesity: a review of currently used antiobesity drugs and new compounds in clinical development].
Postepy higieny i medycyny doswiadczalnej (Online) · 2007
- Review of earlier workObesity drugs in clinical development.
Current opinion in investigational drugs (London, England : 2000) · 2006
Spot an error? corrections@peptidesearch.org